Cipher Pharmaceuticals Inc.
CPHRF
$7.85
-$0.07-0.88%
| Weiss Ratings | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Reward Grade | B | |||
| Rating Factors | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.45 | |||
| Price History | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.99% | |||
| 30-Day Total Return | -19.47% | |||
| 60-Day Total Return | -28.89% | |||
| 90-Day Total Return | -33.91% | |||
| Year to Date Total Return | -20.14% | |||
| 1-Year Total Return | 49.24% | |||
| 2-Year Total Return | 179.86% | |||
| 3-Year Total Return | 423.33% | |||
| 5-Year Total Return | 1,186.89% | |||
| 52-Week High % Change | -46.23% | |||
| 52-Week Low % Change | 58.27% | |||
| Price | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.60 | |||
| 52-Week Low Price | $4.96 | |||
| 52-Week Low Price (Date) | Mar 15, 2024 | |||
| 52-Week High Price (Date) | Aug 29, 2024 | |||
| Valuation | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 200.80M | |||
| Enterprise Value | 230.12M | |||
| Price/Earnings (TTM) | 12.39 | |||
| Earnings Per Share (TTM) | 0.63 | |||
| Earnings Per Share Growth | -49.60% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.62 | |||
| Price/Book (Q) | 2.03 | |||
| Enterprise Value/Revenue (TTM) | 8.70 | |||
| Price | $7.85 | |||
| Enterprise Value/EBITDA (TTM) | 18.30 | |||
| Enterprise Value/EBIT | 23.28 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 25.69M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 905 602 5840 | |||
| Address | 5750 Explorer Drive Mississauga, ON L4W 0A9 | |||
| Website | www.cipherpharma.com | |||
| Country | Canada | |||
| Year Founded | 2000 | |||
| Profitability | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 37.34% | |||
| Profit Margin | 59.92% | |||
| Management Effectiveness | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.06% | |||
| Return on Equity | 17.98% | |||
| Income Statement | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 26.46M | |||
| Total Revenue (TTM) | 26.46M | |||
| Revenue Per Share | $1.03 | |||
| Gross Profit (TTM) | 21.38M | |||
| EBITDA (TTM) | 12.57M | |||
| EBIT (TTM) | 9.88M | |||
| Net Income (TTM) | 15.86M | |||
| Net Income Avl. to Common (TTM) | 15.86M | |||
| Total Revenue Growth (Q YOY) | 70.90% | |||
| Earnings Growth (Q YOY) | -95.97% | |||
| EPS Diluted (TTM) | 0.63 | |||
| EPS Diluted Growth (Q YOY) | -96.30% | |||
| Balance Sheet | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 9.52M | |||
| Cash Per Share (Q) | $0.37 | |||
| Total Current Assets (Q) | 29.06M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 98.86M | |||
| Current Ratio (Q) | 2.003 | |||
| Book Value Per Share (Q) | $3.86 | |||
| Total Assets (Q) | 153.86M | |||
| Total Current Liabilities (Q) | 14.51M | |||
| Total Debt (Q) | 40.75M | |||
| Total Liabilities (Q) | 55.00M | |||
| Total Common Equity (Q) | 98.86M | |||
| Cash Flow | CPHRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -80.18M | |||
| Cash from Financing (TTM) | 34.46M | |||
| Net Change in Cash (TTM) | -32.56M | |||
| Levered Free Cash Flow (TTM) | -78.71M | |||
| Cash from Operations (TTM) | 13.08M | |||
